Skip to content
Ritanserin
Ritanserin is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target 5-hydroxytryptamine receptor 1B, alpha-1D adrenergic receptor, 5-hydroxytryptamine receptor 7, 5-hydroxytryptamine receptor 2C, alpha-1A adrenergic receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 1D, 5-hydroxytryptamine receptor 6, alpha-1B adrenergic receptor, and 5-hydroxytryptamine receptor 2B.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
1 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cocaine-related disordersD019970F14—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRITANSERIN
INNritanserin
Description
Ritanserin is a thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action. It has a role as a dopaminergic antagonist, a serotonergic antagonist, an antipsychotic agent, an anxiolytic drug, an antidepressant and an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor. It is an organofluorine compound, a member of piperidines and a thiazolopyrimidine.
Classification
Small molecule
Drug classserotonin 5-HT2 receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1
Identifiers
PDB6BQH
CAS-ID87051-43-2
RxCUI42373
ChEMBL IDCHEMBL267777
ChEBI ID64195
PubChem CID5074
DrugBankDB12693
UNII ID145TFV465S (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
HTR1B
HTR1B
ADRA1D
ADRA1D
HTR7
HTR7
HTR2C
HTR2C
ADRA1A
ADRA1A
HTR1A
HTR1A
HTR5A
HTR5A
HTR2A
HTR2A
HTR1D
HTR1D
HTR6
HTR6
ADRA1B
ADRA1B
HTR2B
HTR2B
Organism
Homo sapiens
Gene name
HTR1B
Gene synonyms
HTR1DB
NCBI Gene ID
3351
Protein name
5-hydroxytryptamine receptor 1B
Protein synonyms
5-HT-1D-beta, 5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled, S12, Serotonin 1D beta receptor, Serotonin receptor 1B
Uniprot ID
Q4VAY7
Mouse ortholog
Htr1b (15551)
5-hydroxytryptamine receptor 1B (P28334)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,180 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details